T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.
about
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.Mesothelin-Targeted CARs: Driving T Cells to Solid TumorsCAR T cells for solid tumors: armed and ready to go?The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical OverviewT Cells Deficient in the Tyrosine Phosphatase SHP-1 Resist Suppression by Regulatory T Cells.CAR-modified T-cell therapy for cancer: an updated review.Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumorsSelective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.Neuroblastoma: developmental biology, cancer genomics and immunotherapy.Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activityGenetically modified T-cell therapy for osteosarcomaGenetic modification of human T lymphocytes for the treatment of hematologic malignancies.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsComparison of naïve and central memory derived CD8(+) effector cell engraftment fitness and function following adoptive transfer.The role of E3 ubiquitin ligase Cbl proteins in interleukin-2-induced Jurkat T-cell activation.Immunology and immunotherapy of neuroblastoma4-cholesten-3-one suppresses lung adenocarcinoma metastasis by regulating translocation of HMGB1, HIF1α and Caveolin-1Design and development of therapies using chimeric antigen receptor-expressing T cellsGenetic engineering of T cells for the immunotherapy of haematological malignancies.Advances in chimeric antigen receptor immunotherapy for neuroblastoma.Genetically modified T cells to target glioblastoma.CD28z CARs and armored CARsChimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.Enhanced antitumor activity mediated by human 4-1BB-engineered T cells.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.Cell death-based treatment of neuroblastoma.
P2860
Q26744624-48994DBF-82CC-455C-8086-1E6D661B944DQ26778759-A08179A4-4757-4402-BC04-BA83DB11C06FQ26825489-85B06594-FACC-45F4-BBAD-E9E2635589ABQ28066083-2E91BE76-A489-4667-93EC-DF1904961AE9Q30252330-7075F48B-D229-4C18-80D9-2FF429CB823AQ34044213-64CC8052-DAB0-4689-80D1-D37E67174623Q34052580-A8AD774B-6565-47D1-9011-D9A3A6958239Q34458364-B760F3AE-FBA2-4FC1-8B69-E63D2E4C433FQ35283020-7CC5F026-06BC-4CCF-8922-E4F3C5417454Q35623465-D48CF8E0-C2BA-4812-969E-58C5D8094722Q35756547-E100142C-9156-43C1-B506-83C9B971F6BAQ36198232-6EF9CEF8-2BCF-48F0-A6C7-B45B9C4A9A3DQ36366557-3C0B9F73-A990-4036-8679-05685DC1DB4DQ36470354-902F3618-B0FF-455F-9B3D-BDA4E552C004Q36597392-5697FAEA-F96B-46F4-BE0C-2259675BB55FQ36754726-0438AD01-E992-413F-8EFD-68464D55FD2AQ36856798-84AE3498-24B4-4894-815C-FA27DF4FB87EQ37330906-DA8AC144-B34A-45EC-8A68-F8414F6F861AQ37418289-CE6B9B42-1C7C-4913-975D-AB52F0D66E4BQ37965815-43C3666D-73BB-4264-9968-0C01EC6ED934Q38170885-64E48A43-3164-4275-9F98-6C42CDB2C3CEQ38178690-22CBB28C-589F-4669-8CD4-C4CDBCFC39ADQ38199347-AB83D4C4-6592-41EB-8E28-A270BC1452F5Q38400420-F63D7656-5853-4065-91BD-7F50EEF258B4Q38441750-6D89B6D7-46AB-4CE0-86BA-337A84ECDBFFQ38525024-AC950BCB-E134-4CBC-A862-315439B4210FQ38987239-9567795B-FA9D-487E-85C1-470AAF25C7FFQ41033228-5D79B40A-9A04-4179-9D9E-DD9378629D6DQ41686071-0AF9C132-8A35-41E9-A375-C267EE6B935BQ45441936-ECEEFD8B-DAA1-455E-AA91-B22BCAEE14C1Q47285613-BC6FC34D-EB6A-429E-9861-F51C5671A368Q47761448-EFDD4C45-FC9A-47A5-A4C9-4B3DB16E73D9Q47839039-34FD064E-D72A-435C-BA36-BE5A2577FD00
P2860
T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
T cells expressing constitutiv ...... ociated inhibitory mechanisms.
@en
T cells expressing constitutiv ...... ociated inhibitory mechanisms.
@nl
type
label
T cells expressing constitutiv ...... ociated inhibitory mechanisms.
@en
T cells expressing constitutiv ...... ociated inhibitory mechanisms.
@nl
prefLabel
T cells expressing constitutiv ...... ociated inhibitory mechanisms.
@en
T cells expressing constitutiv ...... ociated inhibitory mechanisms.
@nl
P2093
P2860
P356
P1433
P1476
T cells expressing constitutiv ...... sociated inhibitory mechanisms
@en
P2093
Aaron E Foster
Barbara Savoldo
Cliona M Rooney
David M Spencer
Gianpietro Dotti
Leslie E Huye
P2860
P304
P356
10.1038/MT.2010.185
P577
2010-09-14T00:00:00Z